Biosimilar Guidances Could Be Left Out In Cold By White House Regulatory Freeze
Executive Summary
Trump Administration memo could further delay some US FDA guidance documents already past due under the FDA Safety and Innovation Act; attorneys predict uncertainty about, but no immediate impact on, biosimilar and communications draft guidances released in last few weeks of the Obama Administration.
You may also be interested in...
FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say
Costs across the US healthcare system of implementing new suffix-based nomenclature could reach into the billions, stakeholders say in requesting the Office of Management and Budget delay implementation of FDA’s final guidance on nonproprietary naming of biologics pending further analysis.
FDA’s Burden Estimate On Biologic Naming Ignores Downstream Costs, Critics Say
Costs across the US healthcare system of implementing new suffix-based nomenclature could reach into the billions, stakeholders say in requesting the Office of Management and Budget delay implementation of FDA’s final guidance on nonproprietary naming of biologics pending further analysis.
Trump Order Reducing Regulation Might Imperil FDA Good Guidance Practices
Executive order mandating two existing regulations be eliminated for every new one issued includes guidances, raising questions about how FDA will communicate with industry going forward.